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Abstract
Objectives: To compare treatment persistence between two dosages of interferon b-1a in a large observational multiple
sclerosis registry and assess disease outcomes of first line MS treatment at these dosages using propensity scoring to adjust
for baseline imbalance in disease characteristics.
Methods: Treatment discontinuations were evaluated in all patients within the MSBase registry who commenced interferon
b-1a SC thrice weekly (n = 4678). Furthermore, we assessed 2-year clinical outcomes in 1220 patients treated with interferon
b-1a in either dosage (22 mg or 44 mg) as their first disease modifying agent, matched on propensity score calculated from
pre-treatment demographic and clinical variables. A subgroup analysis was performed on 456 matched patients who also
had baseline MRI variables recorded.
Results: Overall, 4054 treatment discontinuations were recorded in 3059 patients. The patients receiving the lower
interferon dosage were more likely to discontinue treatment than those with the higher dosage (25% vs. 20% annual
probability of discontinuation, respectively). This was seen in discontinuations with reasons recorded as ‘‘lack of efficacy’’
(3.3% vs. 1.7%), ‘‘scheduled stop’’ (2.2% vs. 1.3%) or without the reason recorded (16.7% vs. 13.3% annual discontinuation
rate, 22 mg vs. 44 mg dosage, respectively). Propensity score was determined by treating centre and disability (score without
MRI parameters) or centre, sex and number of contrast-enhancing lesions (score including MRI parameters). No differences
in clinical outcomes at two years (relapse rate, time relapse-free and disability) were observed between the matched
patients treated with either of the interferon dosages.
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Conclusions: Treatment discontinuations were more common in interferon b-1a 22 mg SC thrice weekly. However, 2-year
clinical outcomes did not differ between patients receiving the different dosages, thus replicating in a registry dataset derived
from ‘‘real-world’’ database the results of the pivotal randomised trial. Propensity score matching effectively minimised
baseline covariate imbalance between two directly compared sub-populations from a large observational registry.
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Introduction
Primary evidence of therapeutic efficacy is provided by
randomised controlled trials (RCT). However, RCTs require
substantial amount of resources, are time-consuming, associated
with significant costs and employ highly specific selection criteria.
Therefore, patients included in RCTs might not be representative
of the general MS population. Additionally, many potential
treatment comparisons will never be subjected to RCTs because of
lack of commercial interest and large sample sizes required to
show a difference.
Multicentre observational databases have the potential to
describe large, longitudinally evaluated and prospectively assessed
cohorts representative of general populations with specific
conditions. The MSBase registry is an international, observational
database collecting longitudinal data from a large population of
patients with multiple sclerosis (MS; n = 18,886 in February 2012).
This patient population is representative of patients managed in
academic MS centres, which typically also recruit patients for
RCTs. [1] Analyses of treatment outcomes in observational
registries such as MSBase are susceptible to significant biases, e.g.
confounding by treatment indication, recall bias or detection bias.
[2] In such analyses, appropriate methods of bias reduction are
required and need to be validated. The propensity scoring method
is commonly employed to estimate the effect of multiple potential
confounders on treatment assignment. [3,4] The result, a single
propensity score per case, is then used to adjust for individual
confounders of treatment assignment through subject selection,
matching or outcome weighting [5–7].
The pivotal RCT of interferon (IFN) b-1a SC three times
weekly vs. placebo (Prevention of Relapses and Disability by IFN
b-1a Subcutaneously in MS, PRISMS) provided the primary
evidence of its clinical effect in relapsing-remitting MS. [8] In this
RCT, clinical efficacy was no different between the two tested
dosages (22 mg vs. 44 mg). After documenting treatment persis-
tence of first-line use of these IFN dosages in the MSBase dataset,
we assessed clinical outcomes between two propensity score-
matched subpopulations of patients treated with either of the
dosages as first line therapy and compared these results to those
obtained in the PRISMS RCT.
Patients and Methods
Ethics Statement
The MSBase registry was approved by the Melbourne Health
Human Research Ethics Committee, and by the local ethics
committees in all participating centres (or exemptions granted,
according to applicable local laws and regulations). If required,
written informed consent was obtained from enrolled patients.
Database and Study Population
Data extracted from MSBase in February 2012 comprised
longitudinal clinical data of more than 100,000 patient-years from
18,886 patients from 55 MS centres in 25 countries. All subjects
with data recorded within the MSBase registry who received at
least one dose of IFNb-1a SC (Rebif; Merck Serono, Geneva,
Switzerland) prior to February 2012 were included in the
treatment discontinuation analysis.
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The primary analysis of treatment outcomes was performed in
patients treated with first-line Rebif in either available dose (i.e.
22 mg or 44 mg SC three times weekly) for at least two consecutive
years, with no previous exposure to other disease modifying or
immunosuppressive therapy and without switching between the
doses. A prerequisite was availability of demographic and clinical
information (including measures of disability and relapse activity)
throughout the two-year follow-up period. Patients were excluded
on the basis of long disease duration (.10 years from disease
onset) and low disease activity (no relapses within the two years
preceding baseline), in order to approximate the PRISMS study
population.
A secondary analysis was performed in a subset of patients with
investigator-classified cerebral MRI scans within the two years
prior to the baseline visit. This subset was used to calculate a
different propensity score including the MRI variables.
Data Acquisition
The data were recorded in a prospective, observational manner,
as a part of routine clinical practice. Information about MS-related
outcomes was updated during clinic visits, using the iMed patient
record system to enter data at each of the participating centres.
Disability was scored by accredited scorers using the Expanded
Disability Status Scale (EDSS). Quality of the EDSS assessment
was assured by the requirement of online Neurostatus certification
at each of the participating centres. Date of onset of clinical
relapses was recorded. Annualised relapse rate (ARR) was
calculated based on the relapse onsets recorded within the year
preceding treatment initiation (baseline relapse activity) and the
two years following the baseline (on-treatment relapse activity).
Duration of MS was estimated as the time since the patient-
reported first clinical manifestation of the disease (recorded
retrospectively). The presence, relationships and number of
relatives with the diagnosis of MS was recorded in a proportion
of patients. MRI brain scans were performed as part of routine
clinical practice at each of the participating centres. Availability of
T2-weighted imaging with locally reported number of hyperin-
tense cerebral T2 lesions (categorised as 1–8 or 9+ per scan) was
the minimum prerequisite for inclusion in the secondary analysis.
If gadolinium-containing contrast was administered according to
local procedures, gadolinium-enhancing lesions (Gd+) were
evaluated as present or absent.
To assure quality of the analysed data, only information from
centres with at least 10 active records was used, as stipulated in the
study protocol. The minimum prerequisite was at least annual
data updates. For all events, including new symptoms, clinical
relapses, quantification of disability, changes in disease course,
MRI and laboratory investigations and adverse events, a date of
event onset was required. Prior to analysis the recorded data were
verified using a series of automated procedures to identify any
invalid or inconsistent entries.
Analysis of Treatment Discontinuation and Switch
Statistical analyses were carried out using Statistica 10 (Statsoft,
Tulsa, OK, USA) and R software (http://www.R-project.org).
Incidence of treatment discontinuation events with respect to the
recorded reasons for discontinuation was compared between the
treatment dosages using the Andersen-Gill models with Efron
approximation method. These models are used to model time to
recurrent events, compensating for highly variable treatment
exposure and the fact that each subject could consecutively receive
multiple treatments. The models were adjusted for patient age, sex
and country. In selected variables, a ‘‘missing’’ value was allowed
in order to avoid patient exclusions. Cases were censored at the
time of the last visit unless the time of treatment discontinuation
event was specified. Goodness of model fit was evaluated using the
Akaike information criterion. Initiation of Rebif 44 mg within a
month of discontinuing Rebif 22 mg was considered as treatment
escalation. Similarly, treatment with Rebif 22 mg within a month
of discontinuing Rebif 44 mg was viewed as treatment de-
escalation.
Analysis of Treatment Outcomes
Treatment outcomes were analysed within selected populations
of patients (see above) matched based on their propensity of
assignment to treatment dosage. All matching procedures were
performed using R, the MatchIt package. [9] The propensity score
was calculated using a logistic regression model with the outcome
variable represented by assignment to the Rebif dosage (with Rebif
22 mg set as the reference category). The model excluding MRI
data was built using the following variables: age, disease duration,
ARR, EDSS category, disease course, number of relatives with
MS and MS centre. The model including the baseline MRI data
contained two additional variables, the number of cerebral T2
lesions (categorical, 1–8 or 9+) and the Gd+ lesion status (not
given, 0 or 1+). No interaction terms were included. The
individual propensity scores (with and without MRI findings)
were calculated as weighted sums of those variables with non-zero
weights (at 0.1 level of statistical significance).
Patients in the two treatment groups were then matched in a 1:1
ratio using nearest neighbour matching without replacement and
discarding from both groups the cases outside the common
support of the distance measure (i.e. the common hull of the
pooled propensity scores). [10,11] Closeness of the match between
the matched patients was evaluated using cumulative and average
distances, analysis of standardised differences and tests of statistical
significance (paired t-test and McNemar test). After assessing
normality of data distribution, treatment outcomes were compared
between the propensity score-matched patients with Wilcoxon
signed-rank test (EDSS, change in EDSS and ARR) and
McNemar test (relapse status) as appropriate. Time free from
relapse was estimated by Kaplan-Meier analysis and proportions
of relapse-free patients were compared between the groups with
Log-rank test censored at two years. Cumulative hazard of
multiple relapses was estimated and compared between the groups
with the Andersen-Gill model (see above). Since the differences in
the baseline variables were accounted for during the matching
procedure, no further adjustments for potential confounders were
performed. All reported p-values are two-tailed and for each
analysis p#0.05 was considered significant. The number of
hypothesis-testing procedures was low, therefore no adjustment
for multiple hypothesis testing was applied. Power within the used
statistical models was estimated.
Results
Discontinuation of Treatment
Among the 18,886 patients included in the MSBase registry as
of February 2012, we identified 4678 patients exposed to Rebif. Of
these, 1188 (72% females) were treated with the 22 mg dosage,
2488 (71% females) were treated with the 44 mg dosage and 1002
(72% females) patients received both the dosages at various times.
The average patient age was 36610 years and disease duration
was 767 years (mean 6 SD), for both treatment dosages at the
time of their first initiation. Median treatment period was 2.1 and
2.5 years for the 22 mg and 44 mg dosages, respectively. Total
patient years of follow up were 6480 for the 22 mg and 11,432 for
the 44 mg dosage. Distribution of time on treatment is shown in
Comparison of Interferon Beta 1a Doses in MSBase
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Figure 1. It can be seen that the number of patients treated with
the 22 mg dose for less than 1 year was disproportionately high
compared to the longer treatment durations. In total, 4054
treatment discontinuations were recorded in 3059 patients, 1808
from Rebif 22 mg and 2246 from Rebif 44 mg. There were 192
dosage escalations occurring within the initial 12 months of
treatment with Rebif 22 mg, and these were excluded from further
analyses (red bar in Figure 1). Table 1 provides an overview of the
recorded reasons for treatment discontinuation. It is worth noting
that in a substantial proportion of cases, the reason for
discontinuation was not specified (68%). The annual probability
of treatment discontinuation reached 25% in patients on Rebif
22 mg and 20% in patients on Rebif 44 mg. For more detailed list
of annual probabilities categorised by the recorded reasons for
discontinuation, see Table 1. After adjusting for time on treatment,
age, sex and country, the patients treated with Rebif 22 mg were
more likely to discontinue treatment than those with Rebif 44 mg
(hazard ratio (HR)= 1.4, p = 10216, Andersen-Gill model, see
Figure 2). This difference was apparent in the sub-group analysis
with the reason for discontinuation specified as lack of improve-
ment/progression of disease (HR=1.7, p = 1026), scheduled stop/
convenience (HR=1.6, p = 0.001) or without the reason recorded
(HR=1.5, p = 10216). In contrast, the discontinuation rates due to
adverse events/lack of tolerance did not significantly differ
between the treatment groups (p = 0.98, Andersen-Gill models).
Of the recorded discontinuation events, 466 were evaluated as
escalations of Rebif dosage (including the 192 escalations
occurring within the initial year of treatment). Apart from the
356 events with the reason not recorded, the most frequent reason
for escalation was lack of improvement/progression of disease (94).
Similarly, 123 discontinuation events were considered to be de-
escalations of the Rebif dosage. The reason was not specified in 79
cases and an adverse event/lack of tolerance was recorded in 41
cases.
Disease Outcomes: Validation of Propensity Matched
Outcome Analysis
Primary analysis. To directly compare clinical outcomes of
treatment with Rebif 22 mg and 44 mg as the first disease
modifying treatment used for at least two consecutive years, 614
and 682 patients were selected, respectively (for baseline charac-
teristics see Table 2). The propensity score (i.e. the likelihood of
assignment to the 44 mg Rebif dosage) not including any MRI
parameters was determined predominantly by the MS centre
(OR=0.05–15, p$1027, logistic regression, see Table S1). In
addition, the score was increased by the absence of neurological
disability (i.e. by EDSS step 0; OR=1.8, p = 0.07). After applying
the nearest matching procedure, 610 patients were retained in
each of the treatment groups. Summative distance between the
propensity scores of the matched groups decreased from 229 to
159, with the average pairwise distance decreasing from
0.3460.12 to 0.2660.13 per patient (mean 6 SD). Characteristics
of the matched patients are given in Table 2. No marked
differences in the recorded variables were seen between the
matched groups.
Table 3 compares the clinical outcomes between the matched
groups after two years of treatment with either Rebif dosage.
Neither EDSS nor ARR differed significantly between the groups
(p$0.5, signed-rank test). ARR was reduced by 66% and 68%
compared to baseline in the lower and the higher dosage groups,
respectively. Proportions of patients free from relapses after two
years were 49% and 50% in the Rebif 22 mg and 44 mg groups,
respectively (p = 0.8, McNemar test), with time to first relapse
(p = 0.9, Log-rank test, see Figure 3) and cumulative risk of
relapses comparable between the treatment groups (p = 0.5,
Andersen-Gill model). Power contained within the statistical
models was sufficient to uncover treatment effects of the following
sizes at 90% power and the specified level of statistical significance:
EDSS, 0.25; change in EDSS, 0.18; ARR, 0.09; cumulative
relapse risk, 0.1.
Secondary analysis. The propensity score involving semi-
quantitative MRI parameters at baseline was determined pre-
dominantly by the MS centre (OR=0.2–7, p$0.0001, logistic
regression). In addition, men (OR=2, p= 0.002) and patients with
9 or more T2 lesions (OR=1.8, p = 0.09) were more likely to
receive Rebif 44 mg. The matching procedure retained 226
patients in each group, with summative distance between the
propensity scores of the groups decreasing from 105 to 44 and the
average pairwise distance decreasing from 0.3660.12 to 0.260.1
per patient (mean 6 SD). Table 4 provides group characteristics
before and after matching. Despite the overall decrease in distance
between the two dosage groups, statistically significant differences
in age and the number of hyperintense T2-lesions were not
eliminated by the matching procedure.
Clinical outcomes in this analysis inclusive of baseline MRI
were similar to the outcomes of the larger comparative analysis
detailed above (Table 3). Both EDSS and ARR at two years were
comparable between the matched groups (p$0.9, signed-rank
test). ARR was reduced by 72% and 71% compared to baseline in
the lower and the higher dosage groups, respectively. Proportions
of patients free from relapses at two years were 46% and 51% in
the Rebif 22 mg and 44 mg groups, respectively (p = 0.7, McNemar
test), with time to first relapse (p = 0.1, Log-rank test, see Figure 3)
and cumulative risk of relapses similar in both groups (p = 0.9;
Andersen-Gill model). The models contained 90% power at the
specified level of statistical significance to uncover effect sizes as
follows: EDSS, 0.4; change in EDSS, 0.31; ARR, 0.13; cumulative
relapse risk, 0.2.
Discussion
Using data from a large clinical practice MS registry, MSBase,
we have shown that patients with IFNb-1a SC thrice weekly
(Rebif) in the 22 mg dosage are more likely to discontinue
treatment than those receiving Rebif in the 44 mg dosage. Annual
discontinuation rates reached 25% and 20% in the two treatment
dosages, respectively. Compared to Rebif 44 mg, the 22 mg dosage
was more often discontinued due to perceived insufficient effect or
Figure 1. Exposure to treatment with interferon b-1a SC thrice
weekly. Numbers of patients treated with Rebif recorded within the
MSBase registry (n = 4678) and stratified by time on treatment are
shown. Red bar in year 1 indicates the proportion of patients in whom
dose escalation was a planned procedure. TIW, three times weekly.
doi:10.1371/journal.pone.0063480.g001
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a scheduled stop. In order to compare clinical outcomes of the
original PRISMS trial with real-world practice, we performed
propensity score-matched pairwise analyses of patients receiving
either dosage of Rebif as first-line MS therapy who continued on
their respective dosage for at least two years. In agreement with
the PRISMS trial, our closely matched populations did not show
any effect of Rebif dosage on two-year clinical outcomes.
The mean annual probability of discontinuing Rebif within the
MSBase registry was 23%, which has markedly exceeded the
treatment discontinuation rate reported in the PRISMS study (10–
11% over two years). [8] Similarly, the annual discontinuation
rates due to reported adverse events were marginally higher in our
study compared to the PRISMS trial (3% and 1.5–2.4%,
respectively). Interestingly, the PRISMS and the EVIDENCE
trials reported a dose-dependent incidence of adverse events.
Namely, decreases in leukocyte, neutrophil and lymphocyte
counts, increase in aminotransferase levels and injection site
reactions were found to be more frequent in the groups with
higher dosages of IFNb. [8,12] In the present study, we have
shown a similar trend towards higher annual discontinuation rates
due to adverse events/lack of tolerance in patients receiving Rebif
in the higher dosage, however, this did not reach statistical
significance.
It could be argued that an expected better efficacy of the higher
Rebif dosage (as perceived by patients and clinicians) could have
inflated the discontinuation rate in the Rebif 22 mg group. In this
case the discontinuation events would most likely be followed by
dose escalations. Since the instances of increase in the Rebif
dosage from 22 mg to 44 mg were not included in the analysis of
discontinuation events, we assume that the effect of the perceived
different therapeutic efficacy on treatment discontinuation was
minimal. Overall, the dose escalation was a commonly observed
phenomenon (466 cases, i.e. 26% of all discontinuation events in
the Rebif 22 mg group). Even though lack of effect was the most
commonly specified reason for escalation (in 20% of escalations),
the reason was unspecified for 76% escalation events. It is worth
noting that almost half of the escalations took place within the first
year of treatment initiation, of which 83% were unspecified. We
presume that a high proportion of the early escalations were likely
planned as part of routine treatment initiation procedure used at
some centres. In agreement with this is the observation that
Figure 2. Likelihood of discontinuation by exposure to treatment. Overall proportion of treatment discontinuations in patients treated with
either Rebif dosage is shown (left). Discontinuation rates by the recorded reasons are shown. Hazard ratio (HR) is given where significantly different
from 1, dashed lines represent 95% confidence intervals. Planned dose escalations within the first year of treatment are not included. HR, hazard ratio;
TIW, three times weekly.
doi:10.1371/journal.pone.0063480.g002
Table 1. Discontinuation events.
all patients Rebif 22 mg Rebif 44 mg
adverse event 313 (1.7%) 111 (1.7%) 202 (1.8%)
lack of tolerance 243 (1.4%) 61 (0.9%) 182 (1.6%)
lack of improvement 205 (1.1%) 109 (1.7%) 96 (0.8%)
progression of disease 208 (1.2%) 108 (1.7%) 100 (0.9%)
scheduled stop 117 (0.7%) 55 (0.8%) 62 (0.5%)
convenience 177 (1.0%) 88 (1.4%) 89 (0.8%)
N/A 2599 (14.5%) 1084 (16.7%) 1515 (13.5%)
Total 3862 (21.6%) 1616 (24.9%) 2246 (19.9%)
Data are presented as number of discontinuation events with annual
probability of discontinuation stratified by recorded reasons for
discontinuation. The events were recorded in all patients within the MSBase
ever treated with Rebif. Escalations of treatment dosage planned as part of the
treatment initiation protocol (i.e. occurring within the initial 6 months of
treatment with Rebif 22 mg) were excluded.
doi:10.1371/journal.pone.0063480.t001
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scheduled stop as a reason for discontinuation was more
commonly recorded among patients treated with Rebif 22 mg.
Baseline characteristics of the MSBase cohort included in this
study and the PRISMS study were remarkably similar. Patients
had mean disease duration of 4 years in the MSBase study and 5.3
years in the PRISMS study, with the median EDSS of 2 and 2.5,
respectively. Baseline mean ARR was only marginally different
between the MSBase and PRISMS studies (1.3 vs. 1.5, respec-
tively). Outcomes of the propensity-matched Rebif dosage
comparison confirmed a lack of any statistically significant dose-
dependent differences in relapse frequency or disability, as
demonstrated in PRISMS. [8] Interestingly, our observed on-
treatment ARR was 0.4 (for each dosage), while the PRISMS
reported ARR of 0.91 and 0.86 after two years of treatment with
Rebif 22 mg and 44 mg, respectively. If this difference is to be
attributed to a potential under-reporting of relapses in the MSBase
registry, it should be noted that this, if present, would in all
likelihood apply to either of the treatment groups equally, and thus
would be unlikely to confound the analysis comparing the
outcomes of the two Rebif dosages. Reassuringly, our reported
ARR is comparable to the ARR reported in patients receiving
IFNb-1a in the most recent RCTs (0.3–0.4). [13,14] Also, the
reduction of ARR (66–72%) and proportion of relapse-free
patients (46–51%) at two years were substantially higher in our
study than in the PRISMS trial (39–42% and 27–32%,
respectively). Finally, we showed a much less pronounced increase
in EDSS over two years (0–0.1) compared to the PRISMS study
(0.23–0.24). The PRISMS trial also showed a dose-dependent
effect of IFNb-1a on MRI parameters, which we were not able to
assess, as the quantitative MRI data are not routinely recorded in
the MSBase registry. The major difference potentially accounting
for these large absolute outcome differences between the MSBase
study and the PRISMS randomised trial is the fact that we only
included patients with a two-year treatment completion at either
dose of Rebif. We know that annualised discontinuation rates of
Rebif in the MSBase dataset amount to 23%, therefore the
patients with poor relapse control were likely to be differentially
lost from the two studies. Nonetheless, the results suggest high
treatment efficacy over two years in real-world patients treated
with Rebif (at either dose) as their first DMD.
Importantly, we were able to derive a large patient sub-
population from the MSBase clinical practice registry with
different initial treatment assignations (largely determined by
centre preference) whose two-year outcomes could be compared
using patient pairs that were determined with propensity-score
baseline covariate matching. We obtained a similar primary result
Table 2. Baseline demographic and clinical data in patients unmatched and matched by the propensity score.
Unmatched Matched
Rebif 22 mg Rebif 44 mg Rebif 22 mg Rebif 44 mg Cohen d p
subjects (females) 614 (69%) 682 (68%) 610 (68%) 610 (69%) NS
age (mean 6 SD) 34.769.7 35.569.7 34.769.6 35.769.7 0.11 NS
MS duration (mean 6 SD) 4.062.5 4.162.6 4.062.5 4.262.6 0.08 NS
annualised relapse rate (mean 6 SD) 1.361.0 1.361.0 1.361.0 1.461.0 0.02 NS
EDSS (median (interquartile range)) 2 (1.5, 3.5) 2 (1.5, 3.5) 2 (1.5, 3.5) 2 (1.5, 3.5)
EDSS category [0] 4% 9% 4% 7% NS
[1–1.5] 23% 29% 23% 28%
[2–2.5] 37% 29% 38% 30%
[3–3.5] 20% 15% 20% 15%
[4–9.5] 15% 17% 15% 19%
MS course [CIS] 5% 5% 5% 5% NS
[RRMS] 92% 91% 92% 90%
[SPMS] 3% 3% 3% 3%
[PPMS] 1% 1% 1% 1%
number of relatives with MS [0] 92% 94% 92% 94% NS
[1] 7% 4% 7% 5%
[2+] 1% 2% 1% 1%
CIS, clinical isolated syndrome; EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; PPMS, primary progressive multiple sclerosis; RRMS, relapsing-remitting
multiple sclerosis; SD, standard deviation; SPMS, secondary progressive multiple sclerosis.
doi:10.1371/journal.pone.0063480.t002
Figure 3. Kaplan-Meier plots for the proportion of patients free
from clinical relapses. No statistically significant differences between
the treatment dosages were observed. MRI, magnetic resonance
imaging; TIW, three times weekly.
doi:10.1371/journal.pone.0063480.g003
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Table 3. Clinical outcomes at two years of treatment in the patient groups matched on propensity scores.
All matched patients (n =1220) Matched subgroup with MRI data (n =452)
Rebif 22 mg Rebif 44 mg Rebif 22 mg Rebif 44 mg
annualised relapse rate
mean6SD 0.460.6 0.460.6 0.460.5 0.460.6
median (interquartile range) 0.5 (0, 0.5) 0 (0, 0.5) 0.5 (0, 0.5) 0 (0, 0.5)
relative ARR reduction 66% 68% 72% 71%
time to first relapse
mean6SD [months] 16.569.0 16.269.3 16.068.9 16.669.1
proportion relapse-free 49% 50% 46% 51%
EDSS
mean6SD 2.661.6 2.561.7 2.461.6 2.361.7
median (interquartile range) 2 (1.5, 3.5) 2 (1.5, 3.5) 2 (1.5, 3) 2 (1, 3.5)
EDSS change
mean6SD 0.161.2 0.161.2 0.061.3 0.161.2
median (interquartile range) 0 (20.5, 1) 0 (20.5, 0.5) 0 (20.5, 0.5) 0 (20.5, 1)
All matched patients and the subset with available MRI data are shown.
ARR, annualised relapse rate; EDSS, Expanded Disability Status Scale; MRI, magnetic resonance imaging; SD, standard deviation.
doi:10.1371/journal.pone.0063480.t003
Table 4. Baseline demographic, clinical and MRI data in the sub-group with available MRI, unmatched and matched by the
propensity score.
Unmatched Matched
Rebif 22 mg Rebif 44 mg Rebif 22 mg Rebif 44 mg Cohen d p
subjects (females) 269 (75%) 294 (65%) 226 (70%) 226 (67%) NS
age (mean 6 SD) 33.868.9 35.1610 33.268.9 35.169.9 0.20 0.03
MS duration (mean 6 SD) 4.062.5 3.962.4 4.162.5 4.062.4 0.05 NS
annualised relapse rate (mean 6 SD) 1.561.0 1.461.0 1.561.0 1.461.0 0.06 NS
EDSS (median (interquartile range)) 2.5 (1.5, 3) 2 (1, 3) 2 (1.5, 3) 2 (1, 3.5)
EDSS category [0] 5% 11% 6% 8% NS
[1–1.5] 24% 29% 28% 29%
[2–2.5] 31% 35% 36% 34%
[3–3.5] 15% 25% 19% 17%
[4–9.5] 14% 11% 12% 12%
MS course [CIS] 4% 7% 5% 7% NS
[RRMS] 94% 91% 93% 90%
[SPMS] 1% 2% 2% 2%
[PPMS] 0% 0% 0% 0%
number of relatives with MS [0] 92% 93% 91% 93% NS
[1] 7% 5% 8% 6%
[2+] 1% 0% 1% 0%
MRI brain: T2 lesions [1–8] 93% 70% 91% 77% 0.02
[9+] 7% 30% 9% 23%
MRI brain: Gd+ lesions [0] 88% 73% 87% 80% NS
[1+] 10% 21% 12% 16%
[missing] 1% 6% 1% 4%
CIS, clinical isolated syndrome; EDSS, Expanded Disability Status Scale; MRI, magnetic resonance imaging; MS, multiple sclerosis; PPMS, primary progressive multiple
sclerosis; RRMS, relapsing-remitting multiple sclerosis; SD, standard deviation; SPMS, secondary progressive multiple sclerosis.
doi:10.1371/journal.pone.0063480.t004
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(i.e. the lack of dosage-dependent treatment effect) to that obtained
in the pivotal randomised trial examining the same treatment
outcomes. We therefore believe that imbalance within patient
populations non-randomly assigned to different treatment can
potentially be controlled with propensity-based methods. Such
methods include weighting, stratification, matching and covariate
adjustment. Studies in observational cohorts of patients with MS
had previously employed propensity score-weighted analyses to
evaluate disease outcomes, [5,15–17] propensity score-based
stratification to assess long-term benefits of early versus delayed
immunomodulatory treatment [7,18] and propensity score
matching to evaluate sex difference in response to IFNb. [19]
Combinations of propensity score stratification with other
methods, such as recursive partitioning, were also tested [6].
While our approach provided sufficient power for the subse-
quent analyses and resulted in a patient sample that was likely to
be representative of patient populations at MS centres, it did not
eliminate the bias potentially introduced by unknown confound-
ers. To ameliorate this risk, we have accounted for the location-
specific hidden confounders (e.g. centre-specific dose preferences)
by adjusting our models for treating centre. As the matching
algorithm, we have chosen the nearest neighbour procedure in a
1:1 ratio with a relatively benevolent criterion for excluding the
cases outside the hull of the pooled distance measure. [10] Even
though this did not result in a perfect overlap of the propensity
scores between the two matched populations, it still led to a
marked decrease in the mean distance between the matched
groups. For a perfect overlap to be achieved, a stricter matching
criterion would have been required, which in turn would have
resulted in exclusion of a high number of patients and unnecessary
loss of power. We have therefore chosen to use the criterion that
allowed us to preserve power while achieving a satisfactory match.
We also adjusted our statistical models for age, sex and country,
which we have shown to be related to treatment discontinuation.
[20] However, we were unable to adjust the analyses for change in
disability, as this was usually not recorded at the time of treatment
discontinuation. Moreover, we were unable to include information
about relapse severity and recovery, which was often missing and
the resulting statistical models would most probably be overfitted.
A potential under-estimation of the frequency of treatment
discontinuations due to specific reasons could stem from the
relatively high proportion of discontinuation events with the
reason not specified. Also, baseline cerebral MRI data were
missing in the majority of patients. However, a propensity-
matched subgroup analysis including MRI did not yield results
different to the subgroup analysis excluding MRI. It is of note that
the quality of the MRI data were likely to be variable, as they were
provided by the clinicians using a semi-quantitative evaluation of
MRI lesions carried out in a number of scanners with variable
protocols. However, the number of hyperintense T2-lesions and
the presence/absence of Gd+ lesions were probably the MRI
characteristics that were most likely to influence clinical decision-
making with respect to DMD choice. It should also be noted that
the quality of clinical data recorded in observational registries such
as MSBase is unlikely to be similar to the quality of data
originating from RCTs during the on-treatment period. Paradox-
ically, the quality of data pertaining to the pre-treatment time is
actually likely to be better, as it is generally prospectively recorded
in MSBase prior to treatment start, whereas in clinical trials
disease and relapse history is typically collected retrospectively.
Finally, the inclusion criterion of sustained therapy with Rebif for
at least two years resulted in bias towards selecting patients with
more satisfactory treatment response. We presume that this bias
influenced either of the dosage groups symmetrically and did not
confound the comparison of disease outcomes between the groups.
Conclusion
In this study, we have shown that direct real-world treatment
comparisons can be conducted on registry data. Using the global
MSBase registry data, we conducted a propensity score-based
pairwise patient selection method to compare treatment outcomes
between two doses of IFN b-1a thrice weekly (Rebif 22 mg vs.
Rebif 44 mg). The dosage comparisons in our study with respect to
differences in relapse rate and EDSS change mirrored those
obtained from the pivotal RCT and enabled their broader
generalisation. This method could be of increasing importance
for head-to-head evaluation of the rapidly increasing number of
disease modifying therapies in MS, many of which will never be
compared to each other in RCTs. Although we do not claim that
the results produced by the analyses of the observational registries
can substitute for RCTs, we believe that the described technique
represents a useful and feasible option when RCTs are not feasible
or unlikely to be conducted.
Supporting Information
Table S1 Assignation to treatment dosage by treating
centres. The table shows number of patients assigned to either
Rebif dosage at each of the participating centres. Odds relative to
the reference centre (IT-002) of assignation to the higher dosage
are given. The results were incorporated in the individual
propensity scores.
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